Advances in clinical trials and treatment of the CD40-CD40L pathway as an immune checkpoint have been discussed in detail in the review by Tang et al, and treatment targeting CD40/CD40L in MM still needs to be further explored (137). Here, CD40 is linked to Miyoshi myopathy.